These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 33791707)

  • 1. TMPRSS2 inhibitor discovery facilitated through an
    Peiffer AL; Garlick JM; Wu Y; Soellner MB; Brooks CL; Mapp AK
    bioRxiv; 2021 Mar; ():. PubMed ID: 33791707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TMPRSS2 Inhibitor Discovery Facilitated through an
    Peiffer AL; Garlick JM; Wu Y; Wotring JW; Arora S; Harmata AS; Bochar DA; Stephenson CJ; Soellner MB; Sexton JZ; Brooks CL; Mapp AK
    ACS Med Chem Lett; 2023 Jun; 14(6):860-866. PubMed ID: 37284689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors as Potential Treatment of COVID-19.
    Shrimp JH; Kales SC; Sanderson PE; Simeonov A; Shen M; Hall MD
    ACS Pharmacol Transl Sci; 2020 Oct; 3(5):997-1007. PubMed ID: 33062952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors as Potential Treatment of COVID-19.
    Shrimp JH; Kales SC; Sanderson PE; Simeonov A; Shen M; Hall MD
    bioRxiv; 2020 Aug; ():. PubMed ID: 32596694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat.
    Sun G; Sui Y; Zhou Y; Ya J; Yuan C; Jiang L; Huang M
    J Virol; 2021 Sep; 95(19):e0086121. PubMed ID: 34160253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
    Li K; Meyerholz DK; Bartlett JA; McCray PB
    mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting mechanism for SARS-CoV-2
    Zhao X; Luo S; Huang K; Xiong D; Zhang JZH; Duan L
    Nanoscale; 2021 Nov; 13(45):19218-19237. PubMed ID: 34787160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19.
    Kosinsky Y; Peskov K; Stanski DR; Wetmore D; Vinetz J
    Microbiol Spectr; 2022 Apr; 10(2):e0216721. PubMed ID: 35412356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of TMPRSS2 inhibitors from virtual screening.
    Hu X; Shrimp JH; Guo H; Xu M; Chen CZ; Zhu W; Zakharov A; Jain S; Shinn P; Simeonov A; Hall MD; Shen M
    bioRxiv; 2021 Mar; ():. PubMed ID: 33398276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virtual Screening of Natural Products against Type II Transmembrane Serine Protease (TMPRSS2), the Priming Agent of Coronavirus 2 (SARS-CoV-2).
    Rahman N; Basharat Z; Yousuf M; Castaldo G; Rastrelli L; Khan H
    Molecules; 2020 May; 25(10):. PubMed ID: 32408547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suite of TMPRSS2 Assays for Screening Drug Repurposing Candidates as Potential Treatments of COVID-19.
    Shrimp JH; Janiszewski J; Chen CZ; Xu M; Wilson KM; Kales SC; Sanderson PE; Shinn P; Schneider R; Itkin Z; Guo H; Shen M; Klumpp-Thomas C; Michael SG; Zheng W; Simeonov A; Hall MD
    ACS Infect Dis; 2022 Jun; 8(6):1191-1203. PubMed ID: 35648838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease.
    Kreutzberger AJB; Sanyal A; Ojha R; Pyle JD; Vapalahti O; Balistreri G; Kirchhausen T
    J Virol; 2021 Oct; 95(21):e0097521. PubMed ID: 34406858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity.
    Hoffmann M; Hofmann-Winkler H; Smith JC; Krüger N; Arora P; Sørensen LK; Søgaard OS; Hasselstrøm JB; Winkler M; Hempel T; Raich L; Olsson S; Danov O; Jonigk D; Yamazoe T; Yamatsuta K; Mizuno H; Ludwig S; Noé F; Kjolby M; Braun A; Sheltzer JM; Pöhlmann S
    EBioMedicine; 2021 Mar; 65():103255. PubMed ID: 33676899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The discovery and development of transmembrane serine protease 2 (TMPRSS2) inhibitors as candidate drugs for the treatment of COVID-19.
    Mantzourani C; Vasilakaki S; Gerogianni VE; Kokotos G
    Expert Opin Drug Discov; 2022 Mar; 17(3):231-246. PubMed ID: 35072549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of TMPRSS2 Inhibitors from Virtual Screening as a Potential Treatment of COVID-19.
    Hu X; Shrimp JH; Guo H; Xu M; Chen CZ; Zhu W; Zakharov AV; Jain S; Shinn P; Simeonov A; Hall MD; Shen M
    ACS Pharmacol Transl Sci; 2021 Jun; 4(3):1124-1135. PubMed ID: 34136758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural insights and inhibition mechanism of TMPRSS2 by experimentally known inhibitors Camostat mesylate, Nafamostat and Bromhexine hydrochloride to control SARS-coronavirus-2: A molecular modeling approach.
    Sonawane KD; Barale SS; Dhanavade MJ; Waghmare SR; Nadaf NH; Kamble SA; Mohammed AA; Makandar AM; Fandilolu PM; Dound AS; Naik NM; More VB
    Inform Med Unlocked; 2021; 24():100597. PubMed ID: 34075338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BC-11 is a covalent TMPRSS2 fragment inhibitor that impedes SARS-CoV-2 host cell entry.
    Moumbock AFA; Tran HTT; Lamy E; Günther S
    Arch Pharm (Weinheim); 2023 Jan; 356(1):e2200371. PubMed ID: 36316225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Suite of TMPRSS2 Assays for Screening Drug Repurposing Candidates as Potential Treatments of COVID-19.
    Shrimp JH; Janiszewski J; Chen CZ; Xu M; Wilson KM; Kales SC; Sanderson PE; Shinn P; Itkin Z; Guo H; Shen M; Klumpp-Thomas C; Michael SG; Zheng W; Simeonov A; Hall MD
    bioRxiv; 2022 Feb; ():. PubMed ID: 35169799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Silico Analysis and Synthesis of Nafamostat Derivatives and Evaluation of Their Anti-SARS-CoV-2 Activity.
    Fujimoto KJ; Hobbs DCF; Umeda M; Nagata A; Yamaguchi R; Sato Y; Sato A; Ohmatsu K; Ooi T; Yanai T; Kimura H; Murata T
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening strategy of TMPRSS2 inhibitors by FRET-based enzymatic activity for TMPRSS2-based cancer and COVID-19 treatment.
    Chen Y; Huang WC; Yang CS; Cheng FJ; Chiu YF; Chen HF; Huynh TK; Huang CF; Chen CH; Wang HC; Hung MC
    Am J Cancer Res; 2021; 11(3):827-836. PubMed ID: 33791156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.